| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/26/2004 | CN1151250C Recombinant adenovirus for preventing baby's diarrhea |
| 05/26/2004 | CN1151172C Novel membrane proteine P76 of helicobacter pylori |
| 05/26/2004 | CN1151170C Isolated peptides derived from MAGE tumor rejection antigen precursops which complex with HLA-A2 molecules |
| 05/25/2004 | US6740794 Skewing percentage of females to males in shrimp or prawn |
| 05/25/2004 | US6740744 VMP-like sequences of pathogenic borrelia |
| 05/25/2004 | US6740738 Antibodies binding to polypeptides encoded by the genes |
| 05/25/2004 | US6740522 Rank (receptor activator of neurotrophic factor-kappa b) ligand (rankl) polypeptides; immunoregulatory activity |
| 05/25/2004 | US6740512 Eukaryotic neutral sphingomyelinase (nsmase); used in drugs and in diagnosis |
| 05/25/2004 | US6740511 Comprising mutations at one or more residues within the region of fiber stretching; used in gene therapy |
| 05/25/2004 | US6740506 End selection in directed evolution |
| 05/25/2004 | US6740490 Screening for sensitivity to mystery swine disease virus infection by transfecting cells with cd antigens; animal husbandry |
| 05/25/2004 | US6740485 Identification of genes responsible for the virulence of staphylococcus bacteria, which allows for identification of new anti-bacterial agents and mutants that can be used as vaccines |
| 05/25/2004 | US6740325 Peptide-based vaccine for influenza |
| 05/25/2004 | US6740323 HBV/HCV virus-like particle |
| 05/25/2004 | US6740322 Immunization of dairy cattle with Mig protein |
| 05/21/2004 | WO2004042352A2 Substrates of n-end rule ubiquitylation and methods for measuring the ubiquitylation of these substrates |
| 05/21/2004 | WO2004042042A1 Vaccines against west nile virus |
| 05/21/2004 | WO2004042037A1 P153 and p156 antigens for the immunodiagnosis of canine and human ehrlichioses and uses thereof |
| 05/21/2004 | WO2004041997A2 Immunotherapy regimens in hiv-infected patients |
| 05/21/2004 | WO2004041867A2 Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders |
| 05/21/2004 | WO2004041866A1 Conjugate composition comprising antibodies against cd40 or cd28 |
| 05/21/2004 | WO2004041865A2 Stabilized single domain antibodies |
| 05/21/2004 | WO2004041864A2 Passive hyperimmune antibody therapy in the treatment of anthrax |
| 05/21/2004 | WO2004041863A2 Single domain antibodies directed against interferon- gamma and uses therefor |
| 05/21/2004 | WO2004041862A2 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| 05/21/2004 | WO2004041857A2 Mutant of clostridium difficile toxin b and methods of use |
| 05/21/2004 | WO2004041855A1 Peptides for preventing, diagnosing and treating animal and/or human leptospirosis |
| 05/21/2004 | WO2004041853A2 Hcv vaccine compositions comprising e1 and ns3 peptides |
| 05/21/2004 | WO2004041852A2 Hiv vaccine |
| 05/21/2004 | WO2004041851A2 Vaccine |
| 05/21/2004 | WO2004041846A2 INDUCIBLE LIGAND FOR α1β1 INTEGRIN AND USES |
| 05/21/2004 | WO2004041842A2 Epitopes of hepatitis c virus |
| 05/21/2004 | WO2004041302A1 Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator |
| 05/21/2004 | WO2004041212A2 Apkc isoforms in nervous system disorders and cancer |
| 05/21/2004 | WO2004041200A2 Dna based plasmid formulations and vaccines and prophylactics containing the same |
| 05/21/2004 | WO2004041193A2 HUMAN TYPE II DIABETES GENE-Kv CHANNEL-INTERACTING PROTEIN (KChIP1) LOCATED ON CHROMOSOME 5 |
| 05/21/2004 | WO2004041182A2 M. haemolytica outer membrane protein plpe as a vaccine or vaccine component against shipping fever |
| 05/21/2004 | WO2004041159A2 Composition and method for enhancing immune response of swine |
| 05/21/2004 | WO2004041157A2 Group b streptococcus vaccine |
| 05/21/2004 | WO2004041067A2 Prevention and treatment of synucleinopathic disease |
| 05/21/2004 | WO2004040976A1 Cryogenically protected viral delivery systems and related manufacture and use |
| 05/21/2004 | WO2004027049A3 Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells |
| 05/21/2004 | WO2004022709A3 Epitope sequences |
| 05/21/2004 | WO2004009759A8 Novel proteins in enteroaggregative escherichia coli (eaec) useful for diagnosis and therapy of eaec infections |
| 05/21/2004 | WO2004005476A3 Nucleic acid compositions for stimulating immune responses |
| 05/21/2004 | WO2004003153A9 Live replicating spumavirus vector |
| 05/21/2004 | WO2003094834A3 Mucosal vaccines with chitosan adjuvant and meningococcal antigens |
| 05/21/2004 | WO2003089462A3 Tuberculosis vaccines including recombinant bcg strains expressing alanine dehydrogenase, serine dehydratase and/or glutamine synthetase |
| 05/21/2004 | WO2003088900A3 Solid forms of salts with tyrosine kinase activity |
| 05/21/2004 | WO2003080105A3 Angiogenesis regulator genes, pharmaceutical preparations containing same and uses thereof |
| 05/21/2004 | WO2003078595B1 Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response |
| 05/21/2004 | WO2003072725A3 Recombinant negative strand virus rna expression systems and vaccines |
| 05/21/2004 | WO2003072040A3 Administration of agents for the treatment of inflammation |
| 05/21/2004 | WO2003063802A9 Mixed haptenized tumor cells and extracts and methods of treating or screening for cancer |
| 05/21/2004 | WO2003055440A8 Compositions and methods for the treatement of immune related diseases |
| 05/21/2004 | WO2003049766A8 Method of purifying hepatitis a virus particles and vaccine preparation |
| 05/21/2004 | WO2003004684A3 NUCLEIC ACIDS ENCODING A RECOMBINANT 250 kDa ANTIGEN FROM SPOROZOITES/MEROZOITES OF EIMERIA MAXIMA AND THEIR USES |
| 05/21/2004 | WO2002102307B1 Nucleoside vaccine adjuvants |
| 05/21/2004 | WO2002102306A8 Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy |
| 05/21/2004 | WO2002096923B1 Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes |
| 05/21/2004 | WO2002067862A3 Regulation of the ctl response by macrophage migration inhibitory factor |
| 05/21/2004 | WO2002061105A8 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc) |
| 05/21/2004 | WO2000032745A3 Homologous 28-kilodalton immunodominant protein genes of ehrlichia canis and uses thereof |
| 05/21/2004 | CA2505326A1 Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders |
| 05/21/2004 | CA2505325A1 Stabilized single domain antibodies |
| 05/21/2004 | CA2505316A1 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| 05/21/2004 | CA2505209A1 Hiv vaccine |
| 05/21/2004 | CA2505208A1 Hiv vaccine |
| 05/21/2004 | CA2504762A1 P153 and p156 antigens for the immunodiagnosis of canine and human ehrlichioses and uses thereof |
| 05/21/2004 | CA2504711A1 Hcv vaccine compositions comprising e1 and ns3 peptides |
| 05/21/2004 | CA2504350A1 Apkc isoforms in nervous system disorders and cancer |
| 05/21/2004 | CA2504125A1 Inducible ligand for .alpha.1.beta.1 integrin and uses |
| 05/21/2004 | CA2503561A1 Prevention and treatment of synucleinopathic disease |
| 05/21/2004 | CA2501523A1 Human type ii diabetes gene-kv channel-interacting protein (kchip1) located on chromosome 5 |
| 05/21/2004 | CA2498847A1 Group b streptococcus vaccine |
| 05/20/2004 | US20040097719 At least two oligonucleotides linked at their 3' ends, internucleoside linkages or functionalized nucleobase or sugar to a nonnucleotidic linker, at least one oligonucleotide an immunostimulant having accessible 5' end |
| 05/20/2004 | US20040097706 Streptococcus pyogenes antigens and corresponding dna fragments |
| 05/20/2004 | US20040097703 Cancer antigen peptide for treatment cell proliferative and cancer disorders |
| 05/20/2004 | US20040097584 Chlorogenic acid and an analog thereof for immune system stimulation |
| 05/20/2004 | US20040097464 Mixture of non-sulfated fucose-based oligosaccharides, a cosmetic or pharmaceutical composition comprising said mixture and its use in cosmetics or pharmacy |
| 05/20/2004 | US20040097457 Protein disulfide isomerase and abc transporter homologous proteins involved in the regulation of energy homeostasis |
| 05/20/2004 | US20040097456 Using a cytokine for prophylaxis, therapy and diagnosis of skin related growth disorders in mammals |
| 05/20/2004 | US20040097453 Introducing to the subject, or to a target group of cells from the subject, an expressible polynucleotide encoding a eukaryotic heat shock protein for stimulating a therapeutic immune response |
| 05/20/2004 | US20040097402 Therapy for infections; bactericides; synergistic mixtures |
| 05/20/2004 | US20040096973 Diagnosing and preventing microorganismal infections using iron-restricted conditions; genetic vaccines |
| 05/20/2004 | US20040096939 Modifier of organelle metabolism |
| 05/20/2004 | US20040096921 Human plasma hyaluronidase |
| 05/20/2004 | US20040096916 Using peptides and aberrant cell surface proteins for diagnosis, prognosis and identification of subtpyes of kidney cell tumors |
| 05/20/2004 | US20040096901 Chineric monocllonal antibody for treatment and prevention transplant rejection, psoriasis, inflammatory bowel, autoimmune and allergic disorders |
| 05/20/2004 | US20040096888 Comprises nucleotide sequences coding cyclin dependent kinase (PELOTA) for diagnosis, treatment, prognosis and prevention of cell proliferative, cardoivascular, inflammatory, arthritic disorders |
| 05/20/2004 | US20040096877 For diagnosis/treatment/prevention of inflammation/asthma/ allergies |
| 05/20/2004 | US20040096518 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 05/20/2004 | US20040096467 Drug, in particular for modulating the immunological response for the control of viruses, tumors, bacteria and parasites |
| 05/20/2004 | US20040096465 Novel receptors for $1(helicobater pyroli) and use thereof |
| 05/20/2004 | US20040096464 Inactivated influenza virus vaccine for nasal or oral application |
| 05/20/2004 | US20040096463 Influenza antigen preparation obtainable by the following process, in the manufacture of an intradermal flu vaccine: (i) harvesting of virus-containing material from a culture; (ii) clarification of the harvested material to remove |
| 05/20/2004 | US20040096461 Methods of using the conjugate to immunize subjects against bacterial infections. A conjugate molecule of the invention comprises multiple bacterial capsular polysaccharides linked to a carrier protein. The conjugate molecule provides immune |
| 05/20/2004 | US20040096460 Attenuated forms of the virus produced by mutating specific regions of the viral genome. The virus and mutated forms of the virus may be used to induce the production of antibodies to FIV-141, and in vaccines designed to protect cats from FIV, |
| 05/20/2004 | US20040096457 Treatment and prevention of ebv infection and ebv-associated disorders |
| 05/20/2004 | US20040096455 Device for transdermally delivering an immunologically active agent, the device comprising: member having a plurality of stratum corneum-piercing microprotrusions and dry coating on said member; said coating, before drying, comprising an |